Document is current
Any future updates will be listed below
-
Authors
Tingen, Hendrea Sanne Aletta https://orcid.org/0000-0002-8572-9428
Groothof, Dion https://orcid.org/0000-0002-1886-4451
Tubben, Alwin https://orcid.org/0000-0001-8414-958X
Bijzet, Johan https://orcid.org/0000-0002-0375-4460
Houwerzijl, Ewout J.
Muntinghe, Friso L. H.
van der Zwaag, Paul A. https://orcid.org/0000-0001-6693-0321
van der Meer, Peter https://orcid.org/0000-0002-9705-4413
Hazenberg, Bouke P. C. https://orcid.org/0000-0003-1827-0482
Slart, Riemer H. J. A. https://orcid.org/0000-0002-5565-1164
Nienhuis, Hans L. A. https://orcid.org/0000-0003-3974-6830
- License Information
-
More Information
Article History
Received: 25 March 2024
Accepted: 22 July 2024
First Online: 8 August 2024
Declarations
:
: Requirement for consent was waived by the institutional review board of the University Medical Centre Groningen (Registration number: 202100405).
: This study was performed in line with the principles of the Declaration of Helsinki. The study was approved by the institutional review board of the University Medical Centre Groningen (Registration number: 202100405).
: H.S.A. Tingen no disclosures.D. Groothof no disclosures.A. Tubben no disclosures.J. Bijzet no disclosures.E.J. Houwerzijl no disclosures.F.L.H. Muntinghe no disclosures.P.A. van der Zwaag has received consultancy and speaker fees from Pfizer and Alnylam.P. van der Meer received grant support and/or consultancy fees from: Novartis, Pharma Nord, Pfizer, Ionis, Astra Zeneca, Vifor Pharma, Pharmacosmos, BridgeBio, NovoNordisk.B.P.C. Hazenberg no disclosures.R.H.J.A. Slart received independent grant support of Pfizer and Siemens Healthineers and is editor in the European Journal of Nuclear Medicine and Molecular Imaging.H.L.A. Nienhuis received consultancy and speaker fee from Pfizer and Alnylam.
